Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes: constipation predominant, diarrhea predominant, and mixed. ICD codes for IBS include a variety of subtypes; this analysis covers IBS-C and IBS without diarrhea. Limited treatment options are available, and only a few drugs have secured FDA approval for IBS-C. Current treatments include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), guanylate cyclase-C agonists (Allergan’s Linzess and Synergy Pharmaceutical’s Trulance), and bicyclic fatty acids (Takeda’s Amitiza and its generic, lubiprostone by Par), all of which are moderately effective treating the disease. Zelnorm, a 5-HT4 receptor agonist, was withdrawn from the market in 2007 but was recently relaunched for women with IBS-C who are younger than 65.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Allergan, Synergy Pharmaceuticals, Takeda, Alfasigma
Key drugs: Linzess, Trulance, Amitiza, lubiprostone (generic), Zelnorm, dicyclomine, hyoscyamine sulphate / scopolamine, SSRIs, SNRIs, tricyclic antidepressants
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.